The discrepancy between preclinical laboratory experiments and observations made in the clinic could be explained by the fact that some KRAS wt tumours can still activate the RAS pathway due to events other than RAS oncogene mutations, such as BRAF or EGFR mutation. This evidence concerns the gene KRAS and neoplasm.